Mercado mundial de denosumab: tendencias de la industria y pronóstico hasta 2030

Análisis y tamaño del mercado de denosumab

La incidencia de la osteoporosis tiende a aumentar con la edad, especialmente en mujeres posmenopáusicas, debido a los cambios hormonales que se producen durante la menopausia. Sin embargo, la osteoporosis también puede afectar a los hombres y a personas más jóvenes. Según la Fundación Internacional de Osteoporosis (IOF), se estima que en todo el mundo 200 millones de mujeres padecen osteoporosis. Además, aproximadamente 1 de cada 3 mujeres mayores de 50 años y 1 de cada 5 hombres mayores de 50 años sufrirán fracturas osteoporóticas a lo largo de su vida.

Data Bridge Market Research analiza que el mercado mundial de denosumab, que era de 2.892,17 millones de dólares en 2022, se disparará hasta los 7.109,92 millones de dólares en 2030 y se espera que experimente una CAGR del 11,9% durante el período de pronóstico. Esto indica el valor de mercado. “Prolia” domina el segmento de clasificación de medicamentos del mercado mundial de denosumab debido a la creciente demanda de un mejor tratamiento para los trastornos relacionados con los huesos.

Además de la información sobre escenarios de mercado como valor de mercado, tasa de crecimiento, segmentación, cobertura geográfica y actores principales, los informes de mercado seleccionados por Data Bridge Market Research también incluyen análisis profundo de expertos, epidemiología de pacientes, análisis de canalización, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Market Definition

Denosumab injection (Prolia) refers to the type of drug that is utilized for treating osteoporosis, which is a condition in which the bones become thin and weak and breaks easily among the women population. The condition occurs mainly in women who have undergone menopause and have an increased risk for fractures.

Global Denosumab Market Dynamics

Drivers

• Increasing Prevalence of Osteoporosis

Osteoporosis is a common condition characterized by decreased bone density and increased risk of fractures. As the global population ages, the prevalence of osteoporosis is expected to rise, driving the demand for medications like Denosumab that can help prevent fractures and improve bone health.

• Growing Awareness and Diagnosis

With increased awareness about osteoporosis and its impact on overall health, more individuals are seeking diagnosis and treatment. This increased awareness and diagnosis contribute to the demand for medications like Denosumab.

• Efficacy and Safety Profile for Expanded Indications

Denosumab has demonstrated efficacy in reducing the risk of fractures and improving bone density in clinical trials. Its safety profile, when used as directed, has been generally well-tolerated. These factors contribute to its popularity and adoption in the market. Denosumab has received approvals for additional indications beyond osteoporosis, such as the prevention of skeletal-related events in patients with bone metastases from solid tumors and the treatment of giant cell tumors of bone. These expanded indications have widened the market for Denosumab.

Opportunities

• Research and Development Proficiencies

Ongoing research and development efforts in the field of bone health provide opportunities for the development of new therapies and combination treatments. Denosumab manufacturers can explore these opportunities to further optimize the efficacy and safety of Denosumab or develop novel treatments that complement its mechanism of action.

• Increasing Aging Population

The global population is aging, with a larger proportion of elderly individuals. As age is a significant risk factor for osteoporosis and other bone-related conditions, this demographic trend presents a substantial opportunity for the Denosumab market to cater to the growing demand for bone health treatments.

Restraints/Challenges

• Competition from Existing Therapies

Denosumab faces competition from other established therapies for osteoporosis treatment, such as bisphosphonates and selective estrogen receptor modulators. These therapies have been widely used and have a long history of efficacy and safety, making it challenging for Denosumab to gain market share.

• High Cost of Denosumab Therapy and Treatment

Denosumab is a biologic therapy, and biologics often come with a higher cost compared to traditional small molecule drugs. The high cost of Denosumab may limit its accessibility and affordability for some patients, especially in regions with limited healthcare resources or inadequate insurance coverage.

• Long-term Safety and Efficacy Data

While Denosumab has demonstrated efficacy and safety in clinical trials, long-term data on its use beyond several years is limited. The availability of long-term safety and efficacy data is crucial to gain the confidence of healthcare providers and patients, especially for chronic conditions like osteoporosis.

• Complex Reimbursement Challenges

Reimbursement policies and pricing negotiations with healthcare systems and insurance providers can pose challenges for Denosumab manufacturers. The availability of reimbursement and formulary coverage may vary across different regions, impacting patient access and market penetration.

This global denosumab market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Denosumab market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In February 2023, Sandoz announced that the biologics license application (BLA) for its denosumab biosimilar candidate for review had been accepted by the Food and Drug Administration (FDA) for the treatment of premenopausal patients with osteoporosis who are at increased risk of fractures
• In November 2022, Luye Pharma Group’s subsidiary Boan Biotech announced that their Denosumab Injection (Boyoubei) got approval for the product launch in China by the National Medical Products Administration (NMPA) for the treatment of postmenopausal women with osteoporosis at high risk of fractures.

Global Denosumab Market Scope

The global denosumab market is segmented on the basis of drug classification, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Classification

• Prolia
• Xgeva
• Others

 End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Ambulatory Surgical Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Denosumab Market Regional Analysis/Insights

The global denosumab market is analysed, and market size insights and trends are provided by country, drug classification, end-users, and distribution channel as referenced above.

The countries covered in the global denosumab market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.

North America is expected to dominate the global denosumab market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of people having bone disorders, mostly women.

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people, and the growing demand for advanced medical technology for diagnosis and treatment, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

El mercado global de denosumab también le ofrece un análisis detallado del mercado para el crecimiento de cada país en el gasto de atención médica para equipos de capital, la base instalada de diferentes tipos de productos para el mercado global de denosumab, el impacto de la tecnología que utiliza curvas de línea de vida y los cambios en los escenarios regulatorios de la atención médica y su impacto en el mercado global de denosumab. El período de pronóstico es 2015-2020.

Análisis del panorama competitivo y de la cuota de mercado global de denosumab

El panorama competitivo del mercado global de denosumab proporciona detalles por competidores. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento del producto, la amplitud y la variedad del producto, y el dominio de la aplicación. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado global de denosumab.

Algunos de los principales actores que operan en el mercado global de denosumab son:

• Merck & Co., Inc (Estados Unidos)
• Amneal Pharmaceutical Inc (Estados Unidos)
• Industrias farmacéuticas Teva Ltd (Israel)
• Zydus Cadila (India)
• Novartis Ag (Suiza)
• Pfizer Inc (Estados Unidos)
• Astrazeneca (Reino Unido)
• Glaxosmithkline Plc (Reino Unido)
• Compañía Bristol Myers Squibb (Estados Unidos)
• Johnson & Johnson Service Inc (Estados Unidos)
• F. Hoffmann-La Roche Ltd (Suiza)
• Bayer AG (Alemania)
• Amgen Inc (Estados Unidos)
• Sanofi (Francia)
• Biogen (Estados Unidos)
• Regeneron Pharmaceuticals Inc (Estados Unidos)
• Eli Lilly la Compañía (Estados Unidos)
• AbbiVie Inc (Estados Unidos)
• Mylan NV (Estados Unidos)
• Eisai Co., Ltd (Japón)

SKU-67522